Background-We sought to determine the concordance between the accumulating evidence about the impact of tight versus less tight glycemic control in patients with type 2 diabetes mellitus since the publication of UKPDS (UK Prospective Diabetes Study) in 1998 until 2015 with the views about that evidence published in journal articles and practice guidelines. Methods and Results-We searched in top general medicine and specialty journals for articles referring to glycemic control appearing between 2006 and 2015 and identified the latest practice guidelines. To summarize the evidence, we included all published systematic reviews and meta-analyses of contemporary randomized trials of glycemic control measuring patient-important microvascular and macrovascular outcomes, and completed a meta-analysis of their followup extensions. We identified 16 guidelines and 328 statements. The body of evidence produced estimates warranting moderate confidence. This evidence reported no significant impact of tight glycemic control on the risk of dialysis/ transplantation/renal death, blindness, or neuropathy. In the past decade, however, most published statements (77%-100%) and guidelines (95%) unequivocally endorsed benefit. There is also no significant effect on all-cause mortality, cardiovascular mortality, or stroke; however, there is a consistent 15% relative-risk reduction of nonfatal myocardial infarction. 
T ype 2 diabetes mellitus is a growing pandemic and a leading cause of morbidity and mortality. 1 After the DCCT (Diabetes Control and Complications Trial) 2 found that tight glycemic control-a glycohemoglobin A1c (HbA1c) <7% (53 mmol/mol)-could prevent or slow the progression of nephropathy, retinopathy, and neuropathy in patients with type 1 diabetes mellitus, a consensus, extended to patients with type 1 and type 2 diabetes mellitus, emerged: normalizing glycemia prevents diabetes mellitus complications. Guidelines, quality improvement interventions, quality-of-care measures, and patient-directed marketing have since focused on achieving tight glycemic control. [3] [4] [5] Experts labeled clinicians' failure to intensify therapy to achieve this target as clinical inertia and a quality gap. [6] [7] [8] As large randomized clinical trials (RCTs) and their follow-up extensions accrued, experts have interpreted their results as confirming that tight glycemic control prevented microvascular complications of type 2 diabetes mellitus, but they may only prevent cardiovascular complications and mortality in some patients, perhaps those newly diagnosed with this condition. [9] [10] [11] [12] [13] [14] The body of evidence, previously summarized in meta-analyses of large RCTs, seems to confirm this impression (Table I in the Data Supplement) . [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] This evidence has contributed to a consensus reflected in universal guideline recommendations, quality improvement efforts, and clinical decisions all promoting tight glycemic control (HbA1c <6.5 or 7.0%). [26] [27] [28] The same evidence, however, has led some critics to question this consensus. 22, 29, 30 Given the impact on patients, healthcare delivery, and policymaking, the extent to which the consensus about the value of tight glycemic control is consistent with the body of evidence merits clarification. Accordingly, we sought to systematically examine the relationship between the body of evidence about glycemic control in type 2 diabetes mellitus and the contemporary statements on the value of tight glycemic control, when compared with less tight control (HbA1c 7.0%-8.5%), with regard to microvascular and macrovascular outcomes, published in the past decade in top medical journals and clinical practice guidelines.
Methods

Identification and Selection of Published Statements Referring to Glycemic Control
On the basis of the 2014 Journal Citation Reports, 31 Using the search engine for each journal's online site, we searched for glycemic control and alternative spellings in original articles, reviews, letters, commentaries, and editorials appearing between January 2006 and March 2015. Eligible articles offered any statement about the effect of glycemic control on microvascular or macrovascular complications in patients with type 2 diabetes mellitus. We included all eligible articles from general medicine journals, and, because of the large volume of pertinent articles, only those published in the first trimester (January to March) of each year for the specialty journals. Article selection was reproducible: chanceadjusted agreement between the 2 reviewers (R.R.-G. and V.M.M.) tested in 20% of the sample was κ=0.93; 95% confidence interval, 0.85 to 1.00.
With the help of an experienced librarian, we developed an environmental scan strategy using the terms for concepts of diabetes, guidelines, and standards of care, to identify clinical practice guidelines about diabetes mellitus without language restriction. This was strengthened with a search in the National Guideline Clearinghouse. We also consulted Mayo Clinic experts in the field to identify guidelines missed by our search strategy. Eligible guidelines were the latest version published and included statements about the effect of glycemic control on microvascular and macrovascular complications in patients with type 2 diabetes mellitus. Because practice standards from the American Diabetes Association are issued yearly and we believe them to have a broad impact, we included all published in the decade of interest. Chanceadjusted agreement for guideline selection between reviewers was perfect (κ=1.0).
Classification of Statements in Articles and Guidelines
We classified the statements in each article and guideline about the causal relationship between achieving tight glycemic control and the prevention of microvascular and macrovascular complications in patients with type 2 diabetes mellitus because either clearly favorable or uncertain/skeptical. For example, we classified as clearly favorable for microvascular complications and uncertain for macrovascular complications the following statement: data from randomized trials indicate early and aggressive antihyperglycemic therapy significantly reduces the risk of long-term microvascular outcomes. Although the effects of tight glucose control on macrovascular disease are less clear. 32 This classification was reproducible (κ=0.87 for journal articles, κ=1.0 for guidelines). Within each year-2006 to 2015-we estimated the proportion of articles with statements clearly in favor of tight glycemic control to prevent micro-and macrovascular outcomes.
Body of Evidence About Glycemic Control
The body of large randomized trial evidence about glycemic control has been previously summarized, except for the published follow-up extensions of these RCTs. Table I in the Data Supplement describes contemporary large RCTs, their corresponding follow-up extensions and the meta-analyses that include these RCTs. At the individual trial level, we excluded trials that did not test contemporary treatment approaches (eg, Kumamoto), 33 tested multifactorial risk factor reduction (eg, Steno-2), 34 or evaluated specific antihyperglycemic agents (eg, PROactive). 35 However, some reviews included some or all of these studies, and we retained their summaries in our analyses of the body of evidence, subject to sensitivity analyses. When necessary data were not discernible from published studies, as was the case with 2 extension studies, we attempted to contact authors without success. We did not impute any data.
Because the follow-up extension studies have not been summarized, we conducted a meta-analysis. To this end, we extracted the reported hazard or risk ratios and their 95% confidence intervals (CIs) from each extension study and conducted a random effects (DerSimonian and Laird) meta-analysis on each outcome of interest. Because UKPDS (UK Prospective Diabetes Study) 33 control patients also participated as controls in UKPDS 34, we constructed 2 pooled estimates including either one or the other study. Analyses were conducted using the OpenMeta Analyst Software. 36 Examined outcomes were those patients experience and consider important. [37] [38] [39] We selected the following microvascular outcomes as important to patients: end-stage renal disease (ESRD) or dialysis, renal death, blindness, and clinical neuropathy. We also included microalbuminuria and retinal photocoagulation because they are often cited as surrogate outcomes of patient-important microvascular complications and are consistently reported in RCTs. We selected the following macrovascular outcomes as important to patients: all-cause mortality, cardiovascular mortality, nonfatal myocardial infarction (MI), fatal and nonfatal stroke, and peripheral vascular events or amputations. To rate the confidence (high, moderate, low, or very low) in the estimates about the impact of glycemic control on each micro-and macrovascular outcomes from this body of evidence, 38, 40 reviewers worked together using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach, taking into account the risk of bias (methodological quality), directness, consistency, precision of estimates, and risk of biased reporting.
WHAT IS KNOWN
• Tight glycemic control is considered an essential strategy to prevent chronic complications in patients with type 2 diabetes mellitus.
• Practice guideline recommendations, quality improvement programs, and clinical care all promote tight glycemic control.
WHAT THE STUDY ADDS
• The evidence accrued in the past 2 decades consistently demonstrates no significant benefit of tight glycemic control on patient-important micro-and macrovascular outcomes, with the exception of a 15% relative-risk reduction in nonfatal myocardial infarction.
• Despite this, most published statements and all guidelines unequivocally endorse tight glycemic control to prevent microvascular complications, although the benefits for macrovascular outcomes have been tempered after one trial was stopped early because of increased cardiovascular mortality.
• The widespread consensus about the value of tight glycemic control to prevent complications in patients with type 2 diabetes mellitus needs to be recalibrated.
Results
Study Identification
We identified 328 journal articles (Table II in 
Reliability of the Body of Evidence About Microvascular and Macrovascular Outcomes
Using GRADE, we rated the body of evidence as warranting moderate confidence in estimates; it rendered precise (with >400 events for most outcomes) and consistent estimates of direct applicability at moderate risk of bias (because of lack of blinding, loss to follow-up in long-term studies; Tables IX  through XI in the Data Supplement) . 45 However, results were inconsistent for mortality outcomes; also the evidence was sparse for ESRD, renal death, and amputations 46 (Table XII in the Data Supplement). Figure 1A shows the relationship between the estimates of treatment effect for each of the included studies and contemporaneous statements about the value of tight glycemic control on microvascular complications (Table V in the Data Supplement). Since 1998, evidence warranting moderate confidence reports no significant impact of tight glycemic control on the risk of ESRD, renal death, blindness, and clinical neuropathy. The exception was the ADVANCE trial that reported a reduction of 65% (95% CI, 17-85) in the risk of ESRD or dialysis. These estimates are imprecise (very wide CI): important but small benefits, that is, ≤5 fewer ESRD events per 1000 patients treated with tight glycemic control, are still consistent with the data. This imprecision may be because of the lack of effect, the enrollment of low-risk patients, or brief duration of follow-up. 45 Figure 2A also shows a very low (<6%) incidence of all microvascular outcomes and no apparent HbA1c threshold effect on microvascular complications. In contrast, practice guidelines and published statements offer a consistent and confident consensus, with 100% of the guidelines and 77% to 100% of the statements in favor of tight glycemic control to prevent microvascular complications ( Figure 1A ; Tables II  and III in the Data Supplement) .
Relationship Between Statements in Favor of Tight Glycemic Control and the Body of Evidence
Microvascular Complications
Macrovascular Complications
The picture with regard to macrovascular complications is more complex. Tight glycemic control reduces the risk of nonfatal MI by 15%, a consistent finding across the included studies ( Figure 1B ; Table VI in the Data Supplement), although there is no significant effect of tight glycemic control on all-cause and cardiovascular mortality. That a reduction in the risk of nonfatal MI is not associated with a concomitant reduction in the risk of cardiovascular death complicates its interpretation. In fact, the ACCORD study reported significant increases in the risks of all-cause mortality (by 26%; 95% CI, 6-51) and of cardiovascular mortality (by 43%; 95% CI, 11-86) while reporting a significant reduction in the risk of nonfatal MI (by 21%; 95% CI, 5-34). These is evidence of no significant effect of tight glycemic control on the risk of strokes. The effect on amputations is imprecise, in part, due to few events. Recent RCTs have enrolled lower risk participants, reducing the chance of detecting differences if they exist (Figure 2 ). Long-term follow-up studies that accrued more events, however, could not maintain HbA1c <7% in the intervention arm limiting their relevance to current guideline targets ( Figure 2B ; Figure S4 ).
Before the ACCORD trial, a majority of statements declared valuable to achieve tight glycemic control to prevent macrovascular complications (47%-59% 49, 50 After ACCORD, the consensus about the value of tight glycemic control to prevent macrovascular complications withered, with most statements (64%-79%) expressing uncertainty and skepticism. Only two of the guidelines examined, the American Diabetes Association standards published in 2003 and in 2004, declared valuable to achieve tight glycemic control to reduce macrovascular complications.
Discussion Our Findings
Although no significant impact of tight glycemic control on the risks of patient-important nephropathy, retinopathy, or neuropathy is evident, most published statements and practice guidelines endorse its value to prevent microvascular complications. It is possible that these statements rely on indirect evidence (ie, on surrogates of these patient-important outcomes, such as microalbuminuria), but such reliance should reduce their confidence in the value of glycemic control. Although the evidence supports similar cautious skepticism about the impact of glycemic control on mortality and cardiovascular end points, a similarly favorable consensus existed before the ACCORD trial (2008). Since then, the prevailing skepticism, while appropriate, may have failed to account for the consistent apparent benefits of tight glycemic control on the risk of nonfatal MI.
The use of composite end points that include both patientimportant and surrogate outcomes may have contributed to this consensus. The UKPDS was a landmark study that reported a significant decrease in the risk of the composite any diabetes mellitus-related end point with tight glycemic control, 10 although 85% of the effect was limited to one component: retinal photocoagulation. Similarly, ADVANCE investigators reported a 14% relative reduction in the risk of a composite microvascular outcome, with almost all of the effect limited to reductions in the risk of new micro-and macroalbuminuria. 9, 12 ADVANCE researchers also reported a 65% reduction in the risk of ESRD, but this was based on few end points (20 versus 7 events), which renders statistical inference fragile.
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A B Figure 1 . Body of evidence and statements published in journals and guidelines in favor of tight glycemic control in patients with type 2 diabetes mellitus. A, Microvascular complications. The number of guideline statements is presented in parenthesis. ESRD indicates endstage renal disease; and GC, glycemic control. Black, randomized clinical trials; red, follow-up studies of included randomized clinical trials; green, meta-analyses; and orange; meta-analyses of follow-up studies. †Meta-analysis including follow-up UKPDS 33 10 and excluding follow-up UKPDS 34.
11 B, Macrovascular complications. The number of guideline statements is presented in parenthesis. CV indicates cardiovascular; GC, glycemic control. Black, randomized clinical trials; red, follow-up studies of included randomized clinical trials; green, meta-analyses; and orange; meta-analyses of follow-up studies. Because UKPDS 33 10 control patients also participated as controls in UKPDS 34, 11 2 pooled estimates were constructed including either one or the other study. †Meta-analysis including follow-up UKPDS 33 41 and excluding follow-up UKPDS 34. 41 §Meta-analysis including follow-up UKPDS 34 41 and excluding follow-up UKPDS 33. 41 *UKPDS 33. Follow-up (C) includes both fatal and nonfatal myocardial infarction (MI). *UKPDS 33, 10 UKPDS 34, 11 Kelly et al, 19 Trák, 21 Boussageon et al, 15 Hemmingsen et al, 16 Buehler et al, 24 and VADT. Follow-up 44 reports only nonfatal strokes. *UKPDS 34 11 was not included in the 2015 metaanalysis of follow-up studies for cardiovascular mortality and nonfatal MI outcomes, as these outcomes were not reported.
ACCORD reported benefits such as delayed onset of macroalbuminuria, of 3-line worsened visual acuity, of loss of ankle jerk, and of loss of sensation to light touch, but no significant reduction in the risk of patient-important microvascular complications. The VADT also reported reduction in the risk of progression to albuminuria but no significant impact on important microvascular outcomes. 13 This pattern persists in meta-analyses of these RCTs and of their extensions ( Figure 1A) . Thus, the consensus favoring glycemic control may narrowly reflect evidence of benefit of tight glycemic control on surrogate markers of microalbuminuria and retinal photocoagulation.
Limitations and Strengths of Our Analysis
Several concerns may reduce confidence in our analyses. We limited our review of journals to those with highest impact factor, which may capture a consensus that exists only among A, End-of-study mean glycohemoglobin A1c (HbA1c) and rate of microvascular complications and macrovascular complications in the tight (red) and less tight (black) glycemic control groups (square: UKPDS 33 10 ; triangle: UKPDS 34 11 ; circle: ACCORD 9 ; diamond: ADVANCE 12 ; and cross: VADT 13 ). ESRD indicates end-stage renal disease; GC, glycemic control; NNH, number needed to harm; and NNT, number needed to treat. B, End-of-study mean HbA1c and risk of macrovascular complications and severe hypoglycemia in the tight (red) and conventional (black) glycemic control groups of included studies (square: UKPDS 33 10 ; triangle: UKPDS 34 11 ; circle: ACCORD 9 ; diamond: ADVANCE 12 ; and cross: VADT 13 ). MI indicates myocardial infarction.
an elite of researchers and clinicians. That these statements agree with contemporary guidelines strengthen our sense that they represent dominant and influential, rather than fringe, views. Our focus on the past decade (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) , while arbitrary, offers complete coverage: after the UKPDS; before the ACCORD, ADVANCE, and VADT; before and after the publication of the respective extension reports; and present time. As others, we have excluded the Kumamoto (which tested the DCCT intervention in patients with type 2 diabetes mellitus) and UGDP trials (which was stopped early because of harm marred in controversy over its data handling) as individual trials, although their data were represented in some of the included meta-analyses. In addition, the timeframe of our systematic search for meta-analyses of RCTs (2009 to present time) offers complete coverage of all major trials: UKPDS, ACCORD, ADVANCE, and VADT, the latter published last in January 2009.
There is some concerns about placing the UKPDS trial alongside the ACCORD, VADT, or ADVANCE trials because the population are different in terms of duration of diabetes mellitus, glycemic targets, antihyperglycemic agents used, comorbidities, and use of statins. Described as supportive of early aggressive intervention to reduce macrovascular complications, statements often expressed uncertainty about the applicability of the UKPDS results to older patients with comorbidities and more advanced disease. 48, 52 Inspection of Figure 2 , however, reveals how most results of UKPDS, particularly of UKPDS 33, are similar to those of more recent RCTs for both micro-and macrovascular outcomes. Furthermore, a consistent beneficial effect on nonfatal MI is seen across all of these trials, even ACCORD. These findings should reduce our confidence that the results of the UKPDS trial are different to those of latter trials and enable us to consider these trials together as forming a body of evidence.
Our focus on outcomes important to patients may have artificially introduced uncertainty that perhaps is not as evident when one focuses on the effect of glycemic control on surrogate markers or composite end points (eg, any diabetes mellitus-related complications; Figure III in the Data Supplement; Table VIII in the Data Supplement). Surrogate markers, to be valid, need to capture all of the effect of treatment on the outcomes of interest. 53, 54 In the ON-TARGET trial, for example, dual renin-angiotensin-aldosterone blockade prevented albuminuria, but worsened renal outcomes and mortality. 55 The inconsistencies observed in diabetes trials between the effect of glycemic control on surrogates and on outcomes important to patients should lower our confidence in relying on these surrogates for decision making and support the case for larger and longer-term investigations.
Composite end points have been used in all diabetes mellitus trials and may have contributed to obfuscate their interpretation. The UKPDS used the end point "any diabetes mellitus-related end point," which included 14 components and was reduced significantly with glycemic control by 3.2%. Almost all of this reduction, 2.7%, was on the retinal photocoagulation end point, with almost no effect on the other components of greater importance to patients, such as mortality, stroke, amputation, blindness, or need for dialysis. 10 Composite end points that exhibit large gradients of treatment effects and of importance to patients (death and cataract extraction while very different in their importance to patients were both included in the same UKPDS end point) cannot be interpreted, that is, the statement that glycemic control significantly reduced all diabetes mellitus-related complications is potentially misleading. 56, 57 It is plausible that reliance on surrogate and composite end points has contributed to the observed consensus.
Implications for Policy and Practice
We find the overwhelming consensus in favor of tight glycemic control to prevent microvascular complications to be stronger than warranted by the evidence. This consensus likely drives guidelines and quality-of-care interventions focused on glycemic control. It also supports the US Food and Drug Administration policy to approve diabetes mellitus drugs only on the basis of their antihyperglycemic effect without requiring evidence of reduction in the risk of complications. This consensus is also driving studies such as the National Institutes of Health-funded GRADE trial comparing antihyperglycemic drugs on their ability to reduce HbA1c, rather than to reduce the risk of diabetes mellitus complications. 58 Given the uncertain relationship between tight glycemic control and outcomes that matter to patients, this consensus and its downstream consequences to practice, policy, and research deserve review.
As of 2015, the evidence suggests that a skeptical view may be necessary to move diabetes mellitus care forward. The notion that tight glycemic control is clearly beneficial does not hold in the face of the evidence accrued during the past decade, evidence that has fallen short of confirming this notion. The contributions of >27 000 patients participating in RCTs of glycemic control, their clinicians, and the investigators that designed and conducted these trials, question our confident reliance on tight glycemic control as the main or, in some cases only, strategy to prevent complications in patients with type 2 diabetes mellitus. Perhaps as a result, guideline developers are now advocating for selecting less stringent HbA1c targets in patients with recurrent severe hypoglycemia, high-comorbidity burden, or limited-life expectancy. 52, 59 Embracing this skeptical view may spur research to discover new therapeutic approaches to prevent diabetes mellitus complications. Consider the list of evidence-based therapies recommended in guidelines, subject of quality metrics, or routinely prescribed to patients with type 2 diabetes mellitus to prevent retinopathy or neuropathy beyond glycemic control: none. Beyond interventions to improve vascular health that may be helpful, 60 our narrow focus on hyperglycemia has kept this list empty. In this sense, we could not find in clinicaltrials.gov any ongoing trials exploring interventions to prevent microvascular complications. In contrast, where we are skeptical, there is at least 1 National Institutes of Health program announcement calling for RCTs to reduce cardiovascular risk in older adults with diabetes mellitus. 61 Moderation in expectations about the value of tight glycemic control may help advance the individualization of diabetes mellitus care protocols, whispered in recent guidelines, 52 using shared decision making to select glycemic targets and treatments. 62, 63 This, however, will require further research to clarify the tradeoffs involved when selecting different targets (below the point of symptomatic hyperglycemia), and when selecting glycemic control to reduce the residual risk of complications (eg, nonfatal MI) after implementing other evidence-based interventions, such as statins. 64 Recognizing the nature of the evidence also requires the revision of model-based estimates of the economic impact of tight glycemic control 65, 66 and moderation of the exuberant support for policies of tight glycemic control with consequent overtesting and overtreatment. 67, 68 Any moderation will have to be delicately balanced against the risk of therapeutic nihilism. A careful and thoughtful recalibration is likely to promote patient trust in our efforts to advance their best interest. Today, patients with type 2 diabetes mellitus, at least in certain parts of the world, seem to live longer lives with fewer complications. [69] [70] [71] [72] The evidence summarized here requires us to explore factors other than tight glycemic control to explain this improvement and better address the diabetes mellitus epidemic. Exciting new questions and new answers may surface as we look beyond glycemic control.
